Comparative Pharmacology
Head-to-head clinical analysis: ACCRUFER versus IRON DEXTRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRUFER versus IRON DEXTRAN.
ACCRUFER vs IRON DEXTRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCRUFER (ferric maltol) is an oral iron replacement therapy. Ferric iron is complexed with maltol, which enhances absorption. Once absorbed, iron is utilized for hemoglobin synthesis and erythropoiesis.
Iron dextran is a colloidal solution of ferric oxyhydroxide complexed with dextran, which provides a source of iron for hemoglobin synthesis. After intramuscular or intravenous administration, the iron-dextran complex is taken up by the reticuloendothelial system, where iron is released and bound to transferrin for erythropoiesis.
170 mg (1 tablet) orally twice daily (340 mg total daily dose) for adults with iron deficiency anemia, taken on an empty stomach at least 1 hour before or 2 hours after meals.
IM or IV: Calculate total iron deficit using formula: Body weight (kg) × (target Hb - actual Hb) × 0.24 + 500 mg (for iron stores). Administer as single IV infusion or daily IM doses up to 2 mL (100 mg) per day. IV infusion: Dilute in 0.9% NaCl and infuse over 1-6 hours; test dose of 25 mg recommended.
None Documented
None Documented
20 hours (prolonged in hepatic impairment)
The terminal elimination half-life is approximately 5-6 hours for the iron-dextran complex, but the iron released from the complex has a half-life of 2-3 days due to incorporation into erythrocytes and storage pools.
Renal 65% (as unchanged drug), fecal 35%
Iron dextran is primarily excreted via the reticuloendothelial system; iron is incorporated into hemoglobin and stored as ferritin/ hemosiderin. Renal excretion of intact complexes is minimal (<1%). Fecal excretion accounts for less than 1% of the dose.
Category C
Category C
Iron Replacement
Iron Replacement